Welcome to the New Journal Cardiovascular Prevention and Pharmacotherapy https://e-jcpp.org Cardiovascular Prevention and Pharmacotherapy undergoing percutaneous coronary intervention who are at high risk for bleeding. In the original article by Lee et al., 4) another rationale to say goodbye to the widespread use of aspirin was presented. In the study enrolled 1,717 patients with vasospastic angina, the risk of cardiovascular events in the aspirin group was not different from the control group during a two-year follow-up period.